White Papers Directory
Production & Manufacturing
Drug Research
Contract Research & Services
Automation
Latest White Papers
ASEBIO Report 2010
The most salient indicators include the almost 7% rise in the number of biotech R&D personnel employed and the over 5% growth in private R&D expenditure. In addition, companies carrying out biotechnology R&D grew 12%. Other output indicators are also noteworthy, such as the number of patent applications, which virtually doubled (up 85% in the past year). These indicators confirm the efficiency and strength of the national bioindustry sector.
White Papers
White Papers
Reagents for Fine Organic Synthesis – Building Blocks
Renowned for supply of quality screening compound libraries, Enamine, a globally operating medicinal chemistry driven CRO, has developed the world’s largest catalogue of in-house designed and synthesized Building Blocks to complement its large offering of products for early stage drug discovery projects. The company pioneered the Building Block market in the early 2000’s capitalizing on its increasing chemistry experience and the growing number of Building Blocks it had synthesized for library design and numerous synthesis programs.
White Papers
White Papers
Pre-Packaged Diversity Sets of Compounds for Screening
Built on pharmacological profile of compounds rather than on their chemical structure Pharmacological Diversity Set is a brand new tool for HTS campaigns.
White Papers
White Papers
Collection of Compounds for High-Throughput Screening
Enamine’s collection of 1.8 million screening compounds is the world’s largest and most reputable source of small molecules for drug discovery. The majority of the compounds have been synthesized in-house within last 10 years. Each year ca. 200,000 new compounds are added to our collection making it always fresh and interesting for the search of new leads.
White Papers
White Papers
In-Stock-Tomorrow Tangible Structures – REAL Database
REAL DataBase (RDB) is the array of 16 million feasible diverse drug-like structures. The
compounds are synthesized in only 1 step using thoroughly protocolled chemical procedures
from available building blocks.
White Papers
White Papers
Library of Compounds for Fragment-Based Drug Design
The fragment-based approach to drug discovery (FBDD) has been established as an efficient tool in the search for new drugs.1,2 It has been often used since the late 1990s.3 Nowadays a few compounds discovered by FBDD are entering the clinic.4 FBDD has emerged as an alternative approach to traditional lead identification via high-throughput
screening (HTS).
White Papers
White Papers
Pharmacological Diversity Set and 3D Diversity Set
Three-dimensional shape is an essential property of molecules determining their principal ability to bind to biological targets. To maximize biological relevance of a compound library we sought to use this fundamental property in combination with other design approaches.
White Papers
White Papers
Faster, Better, Cheaper: Lean as a Driving Force Behind Pharmaceutical Companies’ Growth
The pharmaceutical industry faces countless challenges: patent expirations, weak product development pipelines, downward pricing pressure and an increasingly burdensome regulatory environment. The most important question for companies is now “How can we position ourselves optimally to be successful in the long term?”
White Papers
White Papers
